Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
2000 1
2001 1
2002 1
2003 1
2005 2
2007 2
2008 2
2009 3
2010 5
2011 8
2012 7
2013 10
2014 14
2015 17
2016 15
2017 15
2018 14
2019 10
2020 23
2021 23
2022 25
2023 21
2024 20
2025 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

222 results

Results by year

Filters applied: . Clear all
Page 1
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber PB, Tadmor T, Lindström V, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Nösslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, van der Klift M, Jäger U, Leys MBL, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink JC, Widmer A, Simon F, De Silva N, Fink AM, Bahlo J, Fischer K, Wendtner CM, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Levin MD, van Oers M, Geisler C, Stilgenbauer S, Hallek M; GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland. Eichhorst B, et al. N Engl J Med. 2023 May 11;388(19):1739-1754. doi: 10.1056/NEJMoa2213093. N Engl J Med. 2023. PMID: 37163621 Clinical Trial.
BACKGROUND: Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking. ...The primary end points were undetec …
BACKGROUND: Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low …
Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021.
GBD 2021 Demographics Collaborators. GBD 2021 Demographics Collaborators. Lancet. 2024 May 18;403(10440):1989-2056. doi: 10.1016/S0140-6736(24)00476-8. Epub 2024 Mar 11. Lancet. 2024. PMID: 38484753 Free PMC article.
Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis.
Flores AM, Hosseini-Nassab N, Jarr KU, Ye J, Zhu X, Wirka R, Koh AL, Tsantilas P, Wang Y, Nanda V, Kojima Y, Zeng Y, Lotfi M, Sinclair R, Weissman IL, Ingelsson E, Smith BR, Leeper NJ. Flores AM, et al. Nat Nanotechnol. 2020 Feb;15(2):154-161. doi: 10.1038/s41565-019-0619-3. Epub 2020 Jan 27. Nat Nanotechnol. 2020. PMID: 31988506 Free PMC article.
We demonstrate that these single-walled carbon nanotubes accumulate within the atherosclerotic plaque, reactivate lesional phagocytosis and reduce the plaque burden in atheroprone apolipoprotein-E-deficient mice without compromising safety, and thereby overcome a key trans …
We demonstrate that these single-walled carbon nanotubes accumulate within the atherosclerotic plaque, reactivate lesional phagocytosis and …
Burn self-stigma: A hybrid concept analysis.
Hemmati Maslakpak M, Ajoudani F, Lotfi M, Alinejad V. Hemmati Maslakpak M, et al. Burns. 2022 Sep;48(6):1405-1416. doi: 10.1016/j.burns.2021.11.007. Epub 2021 Nov 16. Burns. 2022. PMID: 34903418 Review.
METHODS: Using hybrid concept analysis method, we investigated self-stigma in three phases (i.e. theoretical, fieldwork, and final analytical phase). In the first phase we reviewed the literature using PubMed, SCOPUS, Web of Science, Cochrane Library, OVID, SID and Google …
METHODS: Using hybrid concept analysis method, we investigated self-stigma in three phases (i.e. theoretical, fieldwork, and final an …
Comparison of three doses of amikacin on alternate days with a daily dose of meropenem during the same period for the treatment of urinary tract infection with E. coli: a double-blind clinical trial.
Mohsenpour B, Ahmadi A, Azizzadeh H, Ghaderi E, Hajibagheri K, Afrasiabian S, Lotfi G, Farzinpoor Z. Mohsenpour B, et al. BMC Res Notes. 2024 Jan 25;17(1):38. doi: 10.1186/s13104-023-06654-y. BMC Res Notes. 2024. PMID: 38273327 Free PMC article. Clinical Trial.
This study compares three doses of amikacin on alternate days with a daily dose of meropenem in the same period for the treatment of UTIs with E. coli in a double-blind clinical trial. METHODS: The current double-blind clinical trial compares three doses of amikacin on alt …
This study compares three doses of amikacin on alternate days with a daily dose of meropenem in the same period for the treatment of UTIs wi …
Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery.
Fearon WF, Zimmermann FM, De Bruyne B, Piroth Z, van Straten AHM, Szekely L, Davidavičius G, Kalinauskas G, Mansour S, Kharbanda R, Östlund-Papadogeorgos N, Aminian A, Oldroyd KG, Al-Attar N, Jagic N, Dambrink JE, Kala P, Angerås O, MacCarthy P, Wendler O, Casselman F, Witt N, Mavromatis K, Miner SES, Sarma J, Engstrøm T, Christiansen EH, Tonino PAL, Reardon MJ, Lu D, Ding VY, Kobayashi Y, Hlatky MA, Mahaffey KW, Desai M, Woo YJ, Yeung AC, Pijls NHJ; FAME 3 Investigators. Fearon WF, et al. N Engl J Med. 2022 Jan 13;386(2):128-137. doi: 10.1056/NEJMoa2112299. Epub 2021 Nov 4. N Engl J Med. 2022. PMID: 34735046 Clinical Trial.
Evidence-Based Approach to Out-of-Hospital Cardiac Arrest.
Kashef MA, Lotfi AS. Kashef MA, et al. Curr Treat Options Cardiovasc Med. 2021;23(6):43. doi: 10.1007/s11936-021-00924-3. Epub 2021 May 10. Curr Treat Options Cardiovasc Med. 2021. PMID: 33994773 Free PMC article. Review.
222 results